Revealing the full potential of plants through science, passion, and purpose

From concept to industry-ready biotech

A clear need

STH BIOTECH was founded in 2021 by Héloïse and Naomi, two biotechnology engineers united by a shared ambition: to make the therapeutic power of plants more accessible.

Their journey began with a focused interest in medicinal cannabis. While rare cannabinoids held strong therapeutic potential, the limitations of conventional cultivation and extraction methods made them difficult to access in a reliable, scalable, and standardized way.

This conviction was reinforced by personal experiences with relatives facing chronic pain, neurological disorders, and other conditions with no effective treatment. These moments deepened their belief that cannabinoids could offer safer, more efficient alternatives — if only a new way of producing them could be developed.

2020

Selection in Genopole’s Shaker incubation program

2021

Official incorporation of STH BIOTECH

2022

Hiring of the first employee

2023

Winner of the i-Lab Grand Prize › Learn more

2024

Successful Pre-Seed fundraising round (1,5M€)

2025

• 3rd Prize for Women Rising Innovators
• First active ingredient launch: Inawave® BiotecHemp
› Learn more

A scalable solution

After six months of academic development, they brought the project to Genopole, France’s leading biotech hub, where they set up the technology within the Shaker and Gene.IO programs. This environment provided the resources, expertise, and momentum to turn their idea into a scalable innovation platform.

This vision led to the development of SATIVITRO®, a proprietary biotech platform designed to produce plant bioactives without relying on traditional farming. As the technology matured, its potential naturally extended beyond cannabinoids, offering a new standard for accessing a broader range of high-value plant molecules.

Today, STH BIOTECH specializes in the bioproduction and development of plant-based compounds for biotechnological and industrial innovation. What began as a research challenge has become a deeptech company reshaping how plant-based innovation is brought to the world.

Our Vision

Unlock the full potential of plants to advance health, science, and sustainability.

→

We believe that plants hold extraordinary therapeutic and functional value. Yet much of this potential remains untapped, as many valuable compounds are too rare, unstable, or complex to produce using conventional methods.

Our vision is to remove these barriers by establishing plant biotechnology as a reliable and scalable alternative to traditional sourcing. We are committed to demonstrating that sustainability is not a constraint but a true performance factor and to enabling the development of new, high-value solutions for human health, well-being, and scientific innovation.

Our Mission

Make plant-based innovation more accessible, responsible, and scalable.

→

At STH BIOTECH, our mission is to establish new standards in how rare and promising plant molecules are explored, developed, and produced through biotechnology. We focus on bioactives that are difficult to obtain through traditional cultivation and show strong potential for therapeutic, cosmetic, or research applications.

By replacing land-intensive farming with clean and controlled production methods, we aim to reduce the environmental footprint of natural ingredient sourcing — and grow lasting expertise in plant-based innovation.

Our Solution

A new standard for natural compound production.

→

SATIVITRO® is our proprietary bioproduction platform, designed to overcome the limitations of conventional sourcing. It relies on the cultivation of “hairy roots,” fast-growing plant tissues grown in liquid media without soil, light, or pesticides. Once in bioreactors, these roots produce high concentrations of targeted compounds with consistent quality.

SATIVITRO® brings together scientific precision, production reliability, and environmental responsibility — offering a clean and forward-looking model for natural ingredient production.

Our Team

We are a fast-growing team of scientists, engineers, and entrepreneurs, united by shared values — empathy, impact, rigor and integrity — and by the belief that biotech can change the future of plant-based innovation.

Héloïse MAILHAC

Co-founder & CEO

Naomi KAMINSKY

Co-founder & CTO

Héloïse drives the company’s strategy, partnerships, and long-term vision. A biotechnology engineer trained at Sup’Biotech and HEC Challenge+, she is a laureate of Genopole Gene.io, Réseau Entreprendre, and the AgroParisTech Foundation. She also serves as a Board Member of Biomolecules for the BioEconomy.

She leads the company’s strategic development across operations, financing, regulatory affairs, and partnerships — turning long-term vision into execution and ensuring growth within key innovation ecosystems.

Naomi is the scientific force behind the SATIVITRO® platform. A Sup’Biotech graduate specialized in plant biotechnology and natural compound engineering, she initiated the technology during the Genopole Shaker program in 2020. Since then, she has led the scientific and technical development of the company, from proof of concept to industrial scale-up.

Naomi also coordinates research partnerships and manages the growing scientific team behind our innovation pipeline. She is the inventor of two patents and the author of one scientific publication.

Léa RICHARD

Innovation and CSR Manager

Wim MINEUR

R&D Technician

Malak MAZLANI

Head of Bioprocess

Emilie-Katherine TAVERNIER

Plant Molecular Scientist, Post Doc Fellow